Patents Examined by Ruth Davis
  • Patent number: 11187697
    Abstract: The present invention provides, among other things, improved substrate clearance assays for lysosomal enzyme that are particularly useful for measuring potency of lysosomal enzymes or other therapeutics for treatment of lysosomal storage diseases. In particular, the present invention combines a physiologically relevant substrate cell assay and an efficient scintillation based detection method.
    Type: Grant
    Filed: February 18, 2015
    Date of Patent: November 30, 2021
    Assignee: Takeda Pharmaceutical Company Limited
    Inventor: Vijay Chhajlani
  • Patent number: 11185563
    Abstract: The present invention discloses uses of treating, preventing or improving bone diseases by Lactobacillus or a composition including the Lactobacillus. The Lactobacillus and compositions can increase the blood calcium concentration, the trabecular bone volume density, the trabecular thickness, the trabecular number and the bone mineral density of a subject, and reduce trabecular spacing of the subject. Further, the present invention discloses a method for treating a subject diagnosed with a bone disease, through identifying the subject having the bone disease and administering to the subject an effective amount of a composition including at least one of Lactobacillus plantarum GKM3 and Lactobacillus paracasei GKS6, wherein the Lactobacillus plantarum GKM3 is deposited in China General Microbiological Culture Collection Center (CGMCC) with a deposition number of CGMCC 14565 on Aug. 25, 2017, and the Lactobacillus paracasei GKS6 is deposited in CGMCC with a deposition number of CGMCC 14566 on Aug. 25, 2017.
    Type: Grant
    Filed: April 23, 2019
    Date of Patent: November 30, 2021
    Assignee: GRAPE KING BIO Ltd.
    Inventors: Chin-Chu Chen, Yen-Lien Chen, Shin-Wei Lin, Yen-Po Chen, Yang-Tzu Shih, Ching-Wen Lin
  • Patent number: 11172693
    Abstract: A feed additive composition comprising a direct fed microbial in combination with a protease, and a phytase, and a method for improving the performance of a subject or for improving digestibility of a raw material in a feed (e.g. nutrient digestibility, such as amino acid digestibility), or for improving nitrogen retention, or for improving the subject's resistance to necrotic enteritis or for improving feed conversion ratio (FCR) or for improving weight gain in a subject or for improving feed efficiency in a subject or for modulating (e.g. improving) the immune response of the subject or for promoting the growth of beneficial bacteria in the gastrointestinal tract of a subject, which method comprising administering to a subject a direct fed microbial in combination with a protease and a phytase.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: November 16, 2021
    Assignee: DuPont Nutrition Biosciences APS
    Inventor: Luis Fernando Romero Millan
  • Patent number: 11169142
    Abstract: In some embodiments, the invention provides a method for identifying a patient suffering from or suspected of suffering in from a disease associated with the cardiovascular system that is having a subnormal response to the treatment for the disease comprising: subjecting a blood sample from a patient being treated for a disease to a viscoelastic analysis in the presence of a known amount of a thrombolytic agent, to obtain a coagulation characteristic value of the patient; and comparing the coagulation characteristic value of the patient to a coagulation characteristic value of a healthy individual, wherein a difference in the coagulation characteristic value of the patient as compared to the coagulation characteristic value of the healthy individual identifies the patient as a patient having a subnormal response to treatment.
    Type: Grant
    Filed: May 11, 2017
    Date of Patent: November 9, 2021
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventor: Michael P. Chapman
  • Patent number: 11169064
    Abstract: Disclosed is a system for determining fecundity of an embryo utilizing a non¬ invasive grading of early stage embryos (pre-hatching) based upon specific gravity, density and/or estimated weight. The system allows 100% recovery of embryos and can detect differences in growth potential at the earliest stages of development. The system may further enhance the development of embryos by utilization of microfluidic effects during use. The disclosed system supports a wide variety of scenarios for human and animal reproductive technologies and related products and services.
    Type: Grant
    Filed: June 30, 2015
    Date of Patent: November 9, 2021
    Assignee: Texas Tech University System
    Inventors: Samuel D. Prien, Lindsay L. Penrose
  • Patent number: 11160753
    Abstract: Provided herein are transmucosal and transdermal delivery systems comprising: at least one non-ionic surfactant; at least one polyol; and at least one active agent; and optionally further comprising at least one oil. In particular embodiments, the delivery system has an average particle size of from about 5 nm to about 200 nm.
    Type: Grant
    Filed: March 2, 2016
    Date of Patent: November 2, 2021
    Assignee: Medlab Clinical U.S., Inc.
    Inventors: David A. Rutolo, Jr., Sean Michael Hall, Luis Vitetta, Yusi Zhou, Samantha Maree Coulson
  • Patent number: 11149247
    Abstract: Methods for culturing filamentous fungi, in which the filamentous fungi are grown in a colloid of air and a fermentation medium, are provided. The methods result in more rapid and prolific growth of the filamentous fungus than has been achieved by previous methods. Biomats produced by the methods and air-medium colloids for use in the methods are also provided.
    Type: Grant
    Filed: December 10, 2020
    Date of Patent: October 19, 2021
    Assignee: The Fynder Group, Inc.
    Inventors: Michael John Harney, Richard Eugene Macur, Yuval Charles Avniel
  • Patent number: 11141391
    Abstract: Methods of selecting a subject for treatment of amyotrophic lateral sclerosis (ALS) and methods of treatment for subjects having ALS or at risk of developing ALS are provided. The method of selecting subjects for treatment includes obtaining a biological sample from the subject, where the sample is obtained from the subject's gastrointestinal tract or skeletal muscle. The method further includes measuring a biomarker in the subject's sample and selecting the subject for treatment of ALS when the biomarker measurement in the subject's sample is lower or higher relative to a control measurement.
    Type: Grant
    Filed: May 11, 2015
    Date of Patent: October 12, 2021
    Assignee: Rush University Medical Center
    Inventors: Jun Sun, Jingsong Zhou, Shaoping Wu, Jianxun Yi
  • Patent number: 11135252
    Abstract: Embodiments of the disclosure concern methods and compositions related to manipulation of the microbiome in an individual having at least one social behavior deficit. In particular embodiments, an individual has at least one social behavior deficit and was born from a mother who during pregnancy was obese, overweight, or on a high-fat diet during pregnancy or carries mutations associated with neurodevelopmental disorders. In specific embodiments, the individual having at least one social behavior deficit is provided an effective amount of Lactobacillus reuteri for the improvement of at least one symptom of a social behavior deficit.
    Type: Grant
    Filed: April 15, 2017
    Date of Patent: October 5, 2021
    Assignee: Baylor College of Medicine
    Inventors: Mauro Costa-Mattioli, Shelly Alexandra Buffington
  • Patent number: 11129880
    Abstract: The present invention relates to a method for promoting insulin secretion comprising administering an effective amount of plasminogen to a subject; furthermore, the present invention relates to a medicament for promoting insulin secretion.
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: September 28, 2021
    Assignee: Talengen International Limited
    Inventor: Jinan Li
  • Patent number: 11123456
    Abstract: Tissue repair compositions, particularly bone repair compositions, containing demineralized bone fragments and homogenized connective tissues, and methods for making the same. The compositions can be used in the form of an injectable gel, an injectable paste, a paste, a putty, or a rehydratable freeze-dried form.
    Type: Grant
    Filed: April 10, 2019
    Date of Patent: September 21, 2021
    Assignee: LifeNet Health
    Inventors: Leila Masinaei, Lloyd Wolfinbarger, Jr.
  • Patent number: 11116804
    Abstract: The present disclosure relates to methods of treating at least one symptom of a mental disorder or disease of the central nervous system in a subject by modulating the amount of GABA produced in the subject's gut. The present disclosure also relates to methods of culturing the bacterial strain new bacterial strains. Also disclosed are methods of identifying bacterial strains capable of producing GABA, and engineering strains to produce GABA.
    Type: Grant
    Filed: March 13, 2017
    Date of Patent: September 14, 2021
    Assignee: Holobiome, Inc.
    Inventors: Philip Strandwitz, Kim Lewis
  • Patent number: 11116823
    Abstract: The invention provides methods of treating ?-galactosidase A deficiency. Dosage forms, methods of administration, and methods of analyzing human ?-galactosidase A are also included.
    Type: Grant
    Filed: February 14, 2019
    Date of Patent: September 14, 2021
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Douglas A. Treco, Kenneth Loveday, Marianne Borowski
  • Patent number: 11110133
    Abstract: The invention relates to a lyophilized composition comprising a microbiota in its ecosystem, in particular stools, and a mixture of cryoprotectant agents comprising maltodextrin and trehalose, a capsule comprising said lyophilized composition, the use thereof, and methods for the production thereof.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: September 7, 2021
    Assignees: INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT, UNIVERSITE PARIS DESCARTES, UNIVERSITE PARIS DIDEROT—PARIS 7, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS
    Inventors: Nathalie Kapel, Anne-Judith Waligora-Dupriet, Muriel Thomas, Christine Charrueau, Francisca Joly, Camille Mayeur, Véronique Robert, Johanne Delannoy
  • Patent number: 11104878
    Abstract: A Lactobacillus species strain isolated from kimchi or human feces is described. The particular Bacillus species strain described is highly safe by being isolated from kimchi or human feces and has various functionalities, such as excellent blood sugar control activity, anti-obesity activity, blood cholesterol-lowering activity, blood neutral lipid-lowering activity, arteriosclerosis-inhibiting activity or inflammation-inhibiting activity. Accordingly, the particular Bacillus species strain described can be used as a useful food and drug material for preventing, alleviating or treating a metabolic syndrome including diabetes, obesity, fatty liver, glycosuria, hyperlipidemia, cardiovascular disease, hypertension, arteriosclerosis and/or diabetes, an inflammatory disease, and the like.
    Type: Grant
    Filed: September 7, 2016
    Date of Patent: August 31, 2021
    Assignee: UNIVERSITY-INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITY
    Inventors: Dong Hyun Kim, Myung Joo Han, Su Min Lim, Sang Yun Lee
  • Patent number: 11103183
    Abstract: The present disclosure provides a method of assessing periorbital puffiness in a subject by determining if the subject exhibits pseudoherniation of one or more upper eyelid fat pads and/or one or more of the lower eyelid fat pads, determining if the subject exhibits one or more conditions selected from the group consisting of: edema of the fat pad, edema along the soft tissue of the upper and/or lower eyelids, malar mounds due to edema, malar edema, and mild festoons aggravated by edema, and scoring the periorbital puffiness from both determinations.
    Type: Grant
    Filed: April 3, 2020
    Date of Patent: August 31, 2021
    Assignee: STANDARD OF CARE CORPORATION
    Inventors: Iliana E. Sweis, Bryan C. Cressey
  • Patent number: 11105800
    Abstract: The present invention relates to a test element for the detection of an analyte comprising an enzyme, wherein the enzyme is incorporated in a nanocapsule.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: August 31, 2021
    Assignee: ROCHE DIABETES CARE, INC.
    Inventors: Grit Baier, Carina Horn, Katharina Landfester, Anna Musyanovych, Umaporn Paiphansiri
  • Patent number: 11083756
    Abstract: Methods for generating serum-free and/or xenogen-free cardiac explant-derived stem cells (EDC) are provided. These methods may include providing an initial cardiac explant, which has been minced and digested; plating the initial cardiac explant; culturing the plated cardiac explant in serum-free and xenogen-free medium; harvesting EDC cells surrounding or emerging from the plated cardiac explant; and optionally performing static expansion of harvested EDC cells in serum-free and xenogen-free media. Serum-free and/or xenogen-free cardiac EDC cells produced by these methods, as well as methods and uses thereof for the treatment of heart failure in a subject in need thereof, are also provided.
    Type: Grant
    Filed: May 30, 2017
    Date of Patent: August 10, 2021
    Assignee: OTTAWA HEART INSTITUTE RESEARCH CORPORATION
    Inventors: Duncan J. Stewart, David Courtman, Seth Mount, Darryl Davis
  • Patent number: 11077196
    Abstract: Disclosed is an abuse-deterrent pharmaceutical composition comprising a drug with an enzyme-reactive functional group, wherein the drug has an abuse potential, and an enzyme capable of reacting with the enzyme-reactive functional group (a drug-processing enzyme), wherein the drug with the enzyme-reactive functional group is contained in the pharmaceutical composition in a storage stable, enzyme-reactive state and under conditions wherein no enzymatic activity acts on the drug.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: August 3, 2021
    Assignee: G.L. PHARMA GMBH
    Inventors: Georg Guebitz, Katrin Greimel, Martin Brandauer, Daniela Huber, Klaus Bleymaier, Wolfgang Kroutil, Doris Lechner, Christof Wachter, Harald Wagner, Heimo Winkler
  • Patent number: 11065309
    Abstract: Provided herein are compositions containing a lysosomal storage disorder replacement enzyme (LSDRE) and a dispersing agent for subcutaneous injection for treatment of lysosomal storage diseases. Kits and methods of treatment are also provided.
    Type: Grant
    Filed: March 19, 2019
    Date of Patent: July 20, 2021
    Assignee: KINETIQ THERAPEUTICS, LLC
    Inventors: Mingju Cao, Alexander M. Cao